ONCOLOGIA PERSONALIZADA
Grupos de investigación IBS-A-13
ONCOLOGIA PERSONALIZADA
Grupo de investigación integrado por oncólogos médicos, biólogos, farmacéutico y psicooncóloga que tienen como principal objetivo estudiar mecanismos de resistencia, así como identificar factores pronósticos y predictivos de respuesta a los tratamientos oncológicos aplicados que puedan ayudar a establecer tratamientos personalizados minimizando la toxicidad secundaria que se deriva de los mismos. Para ello fundamentalmente se realizan estudio mediante microarrays de genes predictores de respuesta y supervivencia, estudios de genes de resistencia a QT y estudio del perfil de metilación como biomarcador y factor pronóstico en cáncer.
Lineas de investigación
- Estudiar perfil de metilación y su papel como biomarcador pronóstico y predictivo en cáncer
- Identificar factores pronósticos y predictivos de respuesta
- Mecanismos de resistencia a tratamientos oncológicos
Palabras clave
| Miembro |
|---|
| CONDE HERRERO, VERONICA |
| MARTÍNEZ GALÁN, JOAQUINA |
| ORTEGA DOMÍNGUEZ, JOSÉ ANTONIO |
| OCHOA VALLEJO, LUCÍA |
| VALDIVIA BAUTISTA, JAVIER |
| GUTIÉRREZ PASTOR, PILAR |
| CASTILLO PORTELLANO, LUCÍA |
| AMEZCUA HERNANDEZ, VICTOR |
| GARCÍA GARCÍA, JAVIER |
| LUQUE CARO, RAQUEL |
| MAZA SERRANO, ELIZABETH |
| RUIZ VOZMEDIANO, JULIA |
| RODRÍGUEZ GONZÁLEZ, ISABEL |
| GARRIDO PÉREZ, ROSA MARÍA |
| GÓNZALEZ FLORES, ENCARNA |
| DELGADO PÉREZ, JUAN RAMÓN |
| SÁNCHEZ TORO, CARMEN |
Inventores:
Título:
Código:
Inventores:
Título:
Código:
Inventores:
Título:
Código:
Inventores:
Título:
Código:
Inventores:
Título:
Código:
Sepúlveda-Sánchez JM, Vaz MÁ, Balañá C, Gil-Gil M, Reynés G, Gallego Ó, Martínez-García M, Vicente E, Quindós M, Luque R, Ramos A, Ruano Y, Pérez-Segura P, Benavides M, Sánchez-Gómez P, Hernández-Laín A
Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
Neuro-oncology, 2017; 19(11); 1522-1531
FI: 9.384; Q1 / D1
Mañós M, Giralt J, Rueda A, Cabrera J, Martinez-Trufero J, Marruecos J, Lopez-Pousa A, Rodrigo JP, Castelo B, Martínez-Galán J, Arias F, Chaves M, Herranz JJ, Arrazubi V, Baste N, Castro A, Mesía R
Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 1).
Oral oncology, 2017; 70; 58-64
FI: 4.636; Q1 / D1
Irigoyen A, Gallego J, Guillén Ponce C, Vera R, Iranzo V, Ales I, Arévalo S, Pisa A, Martín M, Salud A, Falcó E, Sáenz A, Manzano Mozo JL, Pulido G, Martínez Galán J, Pazo-Cid R, Rivera F, García García T, Serra O, Fernández Parra EM, Hurtado A, Gómez Reina MJ, López Gomez LJ, Martínez Ortega E, Benavides M, Aranda E, Spanish Cooperative Group of Treatment of Digestive Tumors (TTD)
Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.
European journal of cancer (Oxford, England : 1990), 2017; 75; 73-82
FI: 7.191; Q1 / D2
Mesía R, Garcia-Saenz JA, Lozano A, Pastor M, Grau JJ, Martínez-Trufero J, Lambeaz J, Martínez-Galán J, Mel JR, González B, Vázquez S, Mañós M, Taberna M, Cirauqui B, Del Barco E, Casado E, Rubió-Casadevall J, Rodríguez-Jaráiz A, Cruz JJ, Spanish Head And Neck Cancer Cooperative Group (Study TTCC-2007/02)
Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study.
International journal of radiation oncology, biology, physics, 2017; 97(3); 473-480
FI: 5.554; Q1 / D2
Pérez-Ramírez C, Cañadas-Garre M, Alnatsha A, Villar E, Delgado JR, Faus-Dáder MJ, Calleja-Hernández MŸ
Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients.
Pharmacological research, 2016; 111; 877-884
FI: 4.48; Q1 / D2
Morillo, ED; Mesia, R; Klain, JCA; Fernandez, SV; Martinez-Galan, J; Borgonon, MP; Gonzalez-Rivas, C; Daroqui, JC; Berrocal, A; Martinez-Trufero, J; Vera, R; Cruz-Hernandez, JJ
Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study
ORAL ONCOLOGY, 2016; 62;
FI: 4.794; Q1 / D1
Molina D, Pérez-Beteta J, Martínez-González A, Sepúlveda JM, Peralta S, Gil-Gil MJ, Reynes G, Herrero A, De Las Peñas R, Luque R, Capellades J, Balaña C, Pérez-García VM
Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients.
PloS one, 2016; 11(8); e0161484
FI: 2.806; Q1 / D3
Cabeza L, Ortiz R, Arias JL, Prados J, Ruiz Martínez MA, Entrena JM, Luque R, Melguizo C
Enhanced antitumor activity of doxorubicin in breast cancer through the use of poly(butylcyanoacrylate) nanoparticles.
International journal of nanomedicine, 2015; 10; 1291-306
FI: 4.32; Q1 / D2
Berrocal A, Arance A, Lopez Martin JA, Soriano V, Muñoz E, Alonso L, Espinosa E, Lopez Criado P, Valdivia J, Martin Algarra S, Spanish Melanoma Group
Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program.
Melanoma research, 2014; 24(6); 577-83
FI: 2.282; Q1 / D3
Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Petersen LN, Blons H, Collette L, Van Cutsem E, Rougier P, Salazar R, Bedenne L, Emile JF, Laurent-Puig P, Lepage C, PETACC-8 Study Investigators
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
The Lancet. Oncology, 2014; 15(8); 862-73
FI: 24.69; Q1 / D1
Martinez-Galan J, González-Rivas C, Delgado JR
45p * methylation of DNA free in blood sample as prognostic factor in breast cancer subtype.
Ann Oncol, 2014; 25 Suppl 1; i15
FI: 7.04; Q1 / D1
Marchal JA, Lopez GJ, Peran M, Comino A, Delgado JR, García-García JA, Conde V, Aranda FM, Rivas C, Esteban M, Garcia MA
The impact of PKR activation: from neurodegeneration to cancer.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2014; 28(5); 1965-74
FI: 5.043; Q1 / D1
Faivre S, Castellano D, Strosberg J, González E, Salazar R
Pancreatic NETs: where do we stand now?
Cancer metastasis reviews, 2014; 33(1); 361-6
FI: 7.234; Q1 / D1
Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S, ML18147 Study Investigators
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
The Lancet. Oncology, 2013; 14(1); 29-37
FI: 24.725; Q1 / D1
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L, Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
The Lancet. Oncology, 2012; 13(3); 239-46
FI: 25.117; Q1 / D1
Ortiz R, Prados J, Melguizo C, Arias JL, Ruiz MA, Alvarez PJ, Caba O, Luque R, Segura A, Aránega A
5-Fluorouracil-loaded poly(ε-caprolactone) nanoparticles combined with phage E gene therapy as a new strategy against colon cancer.
International journal of nanomedicine, 2012; 7; 95-107
FI: 3.463; Q1 / D3
Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Reboredo M, Manzano JL, Rivera F, Safont MJ, Montagut C, González E, Benavides M, Marcuello E, Cervantes A, Martínez de Prado P, Fernández-Martos C, Arrivi A, Bando I, Aranda E, Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD)
Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study.
PloS one, 2012; 7(10); e47345
FI: 3.73; Q1 / D2
J. Martínez-Galán, JR. Delgado, R. Del Moral, B. Torres-Torres, M. I. Núñez, J. Valdivia, R. Luque, J. Peñalver, S. Ríos-Arrabal, M. Ruiz De Almodóvar
DNA METHYLATION AN EPIGENETIC PATHWAY TO CANCER AND PROMISING TARGET FOR ANTICANCER THERAPY IN BREAST CANCER
European Journal of Cancer supplements, 2010; 8/7;
FI: 9.386; Q1 / D1
Martinez-Galan JR, Perez-Martinez FC, Juiz JM
Differences in glutamate-mediated calcium responses in the ventral cochlear nucleus and inferior colliculus of the developing rat.
Hearing research, 2010; 267(1-2); 46-53
FI: 2.428; Q1 / D1
Gómez A, Escudero P, Chaves M, Rivera F, Marcuello E, González-Flores E
Efficacy and safety of second line treatment with panitumumab plus irinotecan, both given every three weeks, in patients with Wtk-ras metastatic colorrectal cancer
Annals of Oncology, 2010; 21;
FI: 6.452; Q1 / D2
Conde V, González-Astorga B, González-Flores E
18F- FDG Positron Emission Tomography and response to preoperative chemoradiotherapy in rectal
Annals of Oncology, 2010; 21;
FI: 6.452; Q1 / D2
Martínez-Galán J, Del Moral R, Conde V, Torres-Torres B, Valdivia J, Núñez M, González-Flores E, Ríos S, Ortega JA, Delgado JR
EPIGENETICS SILENCING OF THE TUMOR SUPPRESSOR PROTEIN 14-3-3 SIGMA BY METHYLATION IN SPORADIC BREAST CANCER
Annals of Oncology, 2010; 21;
FI: 6.452; Q1 / D2
Martínez-Galán J, Torres-Torres B, Del Moral R, Núñez MI, Valdivia J, González-Flores E, Luque R, Conde V, Ríos S, Delgado JR
ASSOCIATION EPIGENETIC INACTIVATION OF THE ESR1 GENE BY ABERRANT METHYLATION PROMOTER WITH PROGNOSTIC FACTOR IN BREAST CANCER PATIENTS
Annals of Oncology, 2010; 21;
FI: 6.452; Q1 / D2
Martínez-Galán J, Torres B, Del Moral R, Valdivia Bautista J, Núñez MI, Castillo Rubio V, González A, Soberino J, Delgado JR, Ruiz de Almodóvar M
RELATION BETWEEN METHYLATION PROMOTERS GENE AND ESTROGEN RECEPTOR (ERS1) AND HER2/NEU STATUS IN BREAST CANCER PATIENTS
ECCO. European Journal of Cancer, 2010; 8;
FI: 9.386; Q1 / D1
Palma P, Segura I, Conde R, Rodríguez A, del Moral R, González E, Llamas JM, Ferrón JA
Chemoradiation response monitoring in locally advanced rectal cancer: role of 18F-FDG PET
Annals of Oncology, 2010; 21; 158-158
FI: 6.452; Q1 / D2
Palma P, Olmedo C, Cano C, Conde R, Comino AM, Cuadros M, Segura I, González E, del Moral R, Coll E, Blanco A, Bueno P, Ferrón JA
Genomic markers for response to neoadjuvant chemoradiation in locally advanced rectal cancer
Annals of Oncology, 2010; 21; 137-137
FI: 6.452; Q1 / D2
Garcia-Alfonso P, Muñoz-Martin A, Mendez-Ureña M, Quiben-Pereira R, Gonzalez-Flores E, Perez-Manga G
Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group.
British journal of cancer, 2009; 101(7); 1039-43
FI: 4.346; Q1 / D3
Sastre J, Aranda E, Massutí B, Tabernero J, Chaves M, Abad A, Carrato A, Reina JJ, Queralt B, Gómez-España A, González-Flores E, Rivera F, Losa F, García T, Sanchez-Rovira P, Maestu I, Díaz-Rubio E
Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study.
Critical reviews in oncology/hematology, 2009; 70(2); 134-44
FI: 5.269; Q1 / D2
GONZÁLEZ-ASTORGA B, JIMENEZ B, GONZÁLEZ-FLORES E, CONDE-HERRERO V, CASTELLÓN-RUBIO V, LUQUE R, BALLESTEROS P, DEL MORAL R, CONDE-MUIÑO R, DELGADO JR
RADIOTHERAPY AND CHEMOTHERAPY WITH XELODA AND OXALIPLATIN IN PREOPERATIVE PATIENTS WITH RECTAL CANCER STAGE III
ANNALS OF ONCOLOGY, 2009; 20;
FI: 5.647; Q1 / D2
Díaz-Rubio E, Tabernero J, Gómez-España A, Massutí B, Sastre J, Chaves M, Abad A, Carrato A, Queralt B, Reina JJ, Maurel J, González-Flores E, Aparicio J, Rivera F, Losa F, Aranda E, Spanish Cooperative Group for the Treatment of Digestive Tumors Trial
Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007; 25(27); 4224-30
FI: 15.484; Q1 / D1
Rodríguez-González I, Marín C, Longoni SS, Mateo H, Alunda JM, Minaya G, Gutiérrez-Sánchez R, Vargas F, Sánchez-Moreno M
Identification of New World Leishmania species from Peru by biochemical techniques and multiplex PCR assay.
FEMS microbiology letters, 2007; 267(1); 9-16
FI: 2.274; Q1 / D3
